Hematologic Malignancy
Indolent Non-Hodgkin Lymphoma
CI-CAN-00005564Explore in graph →
Hematologic212 active trials12 approved drugs2 evidence items
- NCIt
- C8504
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005564Explore in graph →
Clinical trials
791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (150)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | terminated | Phase 2 | 43 | Asan Medical CenterOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01500538 |
| A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)(VEIL) |
| terminated |
| Phase 2 |
| 1 |
| Peter MacCallum Cancer Centre, AustraliaOTHER |
| 1 |
| Feb 15, 2016 |
| clinicaltrials |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 16, 2015 | clinicaltrials |
| NCT00954005 | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma(R-GO) | terminated | Phase 1 / Phase 2 | 56 | German Low Grade Lymphoma Study GroupOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | terminated | Phase 2 | 12 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 30, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2013 | clinicaltrials |
| NCT00015912 | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | terminated | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00107614 | DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients | terminated | Phase 2 | 12 | University of ArkansasOTHER | 1 | Aug 26, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Apr 21, 2016source: clinicaltrials